PainChek General Discussion, page-66

I hold both stocks and bought back heavily into RAP late last year confident of the trials succeeding the second time around.

PCK have a more difficult commercial route to market. RAP can be integrated into Telehealth companies and access millions of customers rapidly and is a massive takeover target by any tech company. They also hold huge amounts of data and the machine learning algorithm is theirs.

PCK need to approach RACs and license the tech individually which is more expensive. PainChek don’t own the AI software but do have nViso on board as a strategic shareholder in return for licensing their tech.

Comparisons can be made but ultimately they are running their own races.

PCK mentioned they were close to negatotiating a deal with a third party software provider, might be AutumnCare and would certainly boost uptake.